Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A1 | P60842 | 17/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.86 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.86 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.83 |
| ▸ | RELA | Q04206 | 1/20 | 0.83 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.71 |
| ▸ | ABHD10 | Q9NUJ1 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rocagloic Acid SCHEMBL29531721 | 1.00 | EIF4A1 (0.86) | EIF4A1CYP3A4HIF1ANFKB1RELA | |
| Rocagloic Acid SCHEMBL31581598 | 1.00 | EIF4A1 (0.86) | EIF4A1CYP3A4HIF1ANFKB1RELA | |
| Rocagloic Acid SCHEMBL17396445 | 1.00 | EIF4A1 (0.86) | EIF4A1CYP3A4HIF1ANFKB1RELA | |
| Rocagloic Acid SCHEMBL752143 | 1.00 | EIF4A1 (0.86) | EIF4A1CYP3A4HIF1ANFKB1RELA | |
| SCHEMBL15079078 | 0.94 | EIF4A1 (0.86) | EIF4A1CYP3A4HIF1ANFKB1RELA | |
| SCHEMBL18836319 | 0.92 | EIF4A1 (0.86) | EIF4A1CYP3A4HIF1ANFKB1RELA | |
| SCHEMBL31581630 | 0.92 | EIF4A1 (0.86) | EIF4A1CYP3A4HIF1ANFKB1RELA | |
| SCHEMBL17396601 | 0.92 | EIF4A1 (0.86) | EIF4A1CYP3A4HIF1ANFKB1RELA | |
| Aglafolin SCHEMBL20496142 | 0.92 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1ANFKB1RELA | |
| Aglafolin SCHEMBL18835920 | 0.92 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1ANFKB1RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612395-B2 | Rocaglate derivatives and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4554571-A2 | EIF4A INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025076059-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20250115593-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-04-10 | — | — | US | disclosed |
| WO-2024016000-A2 | EIF4A INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2024016000-A2 | EIF4A INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| WO-2013024048-A1 | POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| US-20120238766-A1 | ASYMMETRIC SYNTHESIS OF ROCAGLAMIDES VIA ENANTIOSELECTIVE PHOTOCYCLOADDITION MEDIATED BY CHIRAL BRONSTED ACIDS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| EP-2459220-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | Ascendis Pharma A/S (DK) | 2012-06-06 | — | — | EP | disclosed |
| US-8137509-B2 | Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral brønsted acids | TRUSTEES OF BOSTON UNIVERSITY (US) | 2012-03-20 | — | — | US | disclosed |
| US-8137509-B2 | Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral brønsted acids | TRUSTEES OF BOSTON UNIVERSITY (US) | 2012-03-20 | — | — | US | disclosed |
| WO-2011012715-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | disclosed |
| US-20090299081-A1 | Asymmetric Synthesis of Rocaglamides via Enantioselective Photocycloaddition Mediated by Chiral Bronsted Acids | TRUSTEES OF BOSTON UNIVERSITY (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090299081-A1 | Asymmetric Synthesis of Rocaglamides via Enantioselective Photocycloaddition Mediated by Chiral Bronsted Acids | TRUSTEES OF BOSTON UNIVERSITY (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2007139749-A2 | ASYMMETRIC SYNTHESIS OF ROCAGLAMIDES VIA ENANTIOSELECTIVE PHOTOCYCLOADDITION MEDIATED BY CHIRAL BRONSTED ACIDS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | EIF4A1 4828/4885CYP3A4 1505/4885HIF1A 1202/4885 |
| US-20090299081-A1 | Asymmetric Synthesis of Rocaglamides via Enantioselective Photocycloaddition Mediated by Chiral Bronsted Acids | NFKBIA, NFKB1, NFE2L2 | EIF4A1 4735/4885CYP3A4 423/4885HIF1A 1829/4885 |
| US-20120238766-A1 | ASYMMETRIC SYNTHESIS OF ROCAGLAMIDES VIA ENANTIOSELECTIVE PHOTOCYCLOADDITION MEDIATED BY CHIRAL BRONSTED ACIDS | NFKBIA, NFKB1, NFE2L2 | EIF4A1 4735/4885CYP3A4 423/4885HIF1A 1829/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | EIF4A1 4828/4885CYP3A4 1505/4885HIF1A 1202/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | EIF4A1 4587/4885CYP3A4 209/4885HIF1A 2651/4885 |
| US-12612395-B2 | Rocaglate derivatives and uses thereof | GLRB, SRR, HCAR3 | EIF4A1 4223/4885CYP3A4 1122/4885HIF1A 3117/4885 |
| US-20250115593-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | ACSL3, ADSL, ACSL6 | EIF4A1 4795/4885CYP3A4 1293/4885HIF1A 4561/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | EIF4A1 4587/4885CYP3A4 209/4885HIF1A 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.